99 results on '"Yanokura, M."'
Search Results
2. Multitracer study on transport and distribution of metal ions in plants
- Author
-
Ambe, S., Ohkubo, Y., Kobayashi, Y., Iwamoto, M., Maeda, H., and Yanokura, M.
- Published
- 1995
- Full Text
- View/download PDF
3. “Multitracer” a new tracer technique — Its principle, features, and application
- Author
-
Ambe, S., Chen, S. Y., Ohkubo, Y., Kobayashi, Y., Maeda, H., Iwamoto, M., Yanokura, M., Takematsu, N., and Ambe, F.
- Published
- 1995
- Full Text
- View/download PDF
4. Studies on strongly damped components in relatively light heavy ion reaction systems
- Author
-
Nagame, Y., Nakahara, H., Sueki, K., Kudo, H., Kohno, I., and Yanokura, M.
- Published
- 1984
- Full Text
- View/download PDF
5. Activation analysis of plants within regions of geothermal resource development
- Author
-
Nakahara, H., Yanokura, M., and Murakami, Y.
- Published
- 1977
- Full Text
- View/download PDF
6. Development of a high mass-resolution TOF-ERDA system for a wide mass range
- Author
-
Hong, W., primary, Hayakawa, S., additional, Maeda, K., additional, Fukuda, S., additional, Yanokura, M., additional, Aratani, M., additional, Kimura, K., additional, Gohshi, Y., additional, and Tanihata, I., additional
- Published
- 1997
- Full Text
- View/download PDF
7. Experimental studies of light neutron rich nuclei
- Author
-
Korsheninnikov, A.A., primary, Aleksandrov, D.V., additional, Aoi, N., additional, Doki, Y., additional, Inabe, N., additional, Fujimaki, M., additional, Kobayashi, T., additional, Kumagai, H., additional, Moon, C.-B., additional, Nikolskii, E.Yu., additional, Obuti, M.M., additional, Ogloblin, A.A., additional, Ozawa, A., additional, Shimoura, S., additional, Suzuki, T., additional, Tanihata, I., additional, Watanabe, Y., additional, Yanokura, M., additional, and Yoshida, K., additional
- Published
- 1995
- Full Text
- View/download PDF
8. Observation of 10He
- Author
-
Korsheninnikov, A.A., primary, Yoshida, K., additional, Aleksandrov, D.V., additional, Aoi, N., additional, Doki, Y., additional, Inabe, N., additional, Fujimaki, M., additional, Kobayashi, T., additional, Kumagai, H., additional, Moon, C.-B., additional, Nikolskii, E.Yu., additional, Obuti, M.M., additional, Ogloblin, A.A., additional, Ozawa, A., additional, Shimoura, S., additional, Suzuki, T., additional, Tanihata, I., additional, Watanabe, Y., additional, and Yanokura, M., additional
- Published
- 1994
- Full Text
- View/download PDF
9. Experimental study of 8He + p elastic and inelastic scattering
- Author
-
Korsheninnikov, A.A., primary, Yoshida, K., additional, Aleksandrov, D.V., additional, Aoi, N., additional, Doki, Y., additional, Inabe, N., additional, Fujimaki, M., additional, Kobayashi, T., additional, Kumagai, H., additional, Moon, C.-B., additional, Nikolskii, E.Yu., additional, Obuti, M.M., additional, Ogloblin, A.A., additional, Ozawa, A., additional, Shimoura, S., additional, Suzuki, T., additional, Tanihata, I., additional, Watanabe, Y., additional, and Yanokura, M., additional
- Published
- 1993
- Full Text
- View/download PDF
10. Hydrogen depth profile of Al-alloy vacuum chamber exposed to synchrotron radiation
- Author
-
Kanazawa, K, primary, Yanokura, M, additional, Aratani, M, additional, and Akiyama, H, additional
- Published
- 1993
- Full Text
- View/download PDF
11. Identification of projectile fragments using position sensitive silicon detectors
- Author
-
Liu, W.P., primary, Kubo, T., additional, Kumagai, H., additional, Nakagawa, T., additional, Suzuki, T., additional, Yanokura, M., additional, Tanihata, I., additional, Ito, T., additional, Kashiwagi, T., additional, Kikuchi, J., additional, Yamaguchi, H., additional, Doke, T., additional, Murakami, H., additional, Yanagimachi, T., additional, and Hasebe, N., additional
- Published
- 1990
- Full Text
- View/download PDF
12. Effects of the Fast Neutron Irradiation on Cable Materials.
- Author
-
Kohno, I., Yanokura, M., Motonaga, S., Kamitsubo, H., Yatsuhashi, M., Suematsu, T., and Kobayashi, H.
- Published
- 1986
- Full Text
- View/download PDF
13. Environmental effects of geothermal waste water on the near-by river system
- Author
-
Nakahara, H., Yanokura, M., and Murakami, Y.
- Abstract
Abstract: Environmental effects of geothermal waste water discharged into the neighbouring streams were investigated by ordinary chemical analyses and by the neutron activation method. Results show that serious effects of a large amount of discharge in the past are still retained in the sediments of the near-by water system. It was also found that As and Cs are the best chemical species for tracing the long-standing effects of past discharge.
- Published
- 1978
- Full Text
- View/download PDF
14. Operation Experience of the Riken Variable-Frequency Heavy-Ion Linac, Rilac.
- Author
-
Kase, M., Odera, M., Chiba, Y., Miyazawa, Y., Hemmi, M., Tonuma, T., Inoue, T., Kambara, T., Yanokura, M., Kubo, T., and Ikezawa, E.
- Published
- 1983
- Full Text
- View/download PDF
15. The half-life of 207Bi and decays of 211At and 211Po
- Author
-
Yanokura, M., primary, Kudo, H., additional, Nakahara, H., additional, Miyano, K., additional, Ohya, S., additional, and Nitoh, O., additional
- Published
- 1978
- Full Text
- View/download PDF
16. Statistical Analysis of Preequilibriumα-Particle Spectra and Possible Local Heating
- Author
-
Nomura, T., primary, Utsunomiya, H., additional, Motobayashi, T., additional, Inamura, T., additional, and Yanokura, M., additional
- Published
- 1978
- Full Text
- View/download PDF
17. Cell death and cell-cycle arrest induced by incorporation of [[sup 3] H]thymidine into human haemopoietic cell lines.
- Author
-
Yanokura, M., Takase, K., Yamamoto, K., and Teraoka, H.
- Subjects
- *
THYMIDINE , *HEMATOPOIETIC stem cells , *PHYSIOLOGY - Abstract
Investigates the influence of thymidine incorporated into human hemopoietic cell lines. Examination of cell proliferation, cell viability, DNA fragmentation and expression of caspase-3 and Bcl-2 families; Analysis of cell-cycle of HL-60 using flow cytometry.
- Published
- 2000
18. A new technique for the preparation of very high purity enriched ^1^0^0Mo disk targets
- Author
-
Sugai, I., Aratani, M., Yanokura, M., and Kato, H.
- Published
- 1993
- Full Text
- View/download PDF
19. A continuous scintillation counter using a paraffin scintillator and a solid support
- Author
-
Taklue, M., Fujii, H., Aburai, T., and Yanokura, M.
- Published
- 1995
- Full Text
- View/download PDF
20. Statistical analysis of preequilibrium. cap alpha. -particle spectra and possible local heating
- Author
-
Yanokura, M
- Published
- 1978
- Full Text
- View/download PDF
21. MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel.
- Author
-
Yanokura M, Banno K, and Aoki D
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, DNA Methylation, Drug Resistance, Neoplasm, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Female, Humans, Mice, Mice, Inbred BALB C, Proto-Oncogene Proteins c-met analysis, Proto-Oncogene Proteins c-met antagonists & inhibitors, Proto-Oncogene Proteins c-met physiology, Proto-Oncogene Proteins c-myc analysis, Proto-Oncogene Proteins c-myc physiology, Endometrial Neoplasms drug therapy, MicroRNAs physiology, Paclitaxel pharmacology
- Abstract
Aberrant DNA methylation is widely observed in various types of cancer, and expression of microRNAs (miRNAs/miRs) is suppressed by DNA methylation. The present study explored tumor suppressor miRNAs downregulated by DNA methylation in endometrial cancer cells, as the basis of a novel therapeutic approach for endometrial cancer. Among 821 candidate miRNAs, miR‑34b was identified as an upregulated miRNA after demethylation treatment in all four endometrial cancer cell lines (HEC‑108, SNG‑II, Ishikawa and HHUA) examined. miR‑34b expression with or without demethylation treatment in cancer cells was confirmed by TaqMan quantitative PCR. MYC and MET, the predicted target genes of miR‑34b, were downregulated at both the RNA and protein levels following miR‑34b overexpression. Following miR‑34b treatment, inhibition of cell growth and invasion, and cell cycle arrest were observed in HEC‑108 cells. Sensitivity to paclitaxel was increased in cancer cells with miR‑34b overexpression, compared with untreated cancer cells, but this difference was not identified for cisplatin or doxorubicin. In vivo, combination treatment with miR‑34b and paclitaxel markedly reduced tumor growth compared with treatment with negative control miRNA and paclitaxel. These data suggest that miR‑34b enhances paclitaxel sensitivity in endometrial cancer cells, and that miR‑34b and MET are key targets for treatment of endometrial cancer. The present results may contribute to the development of combination treatment with a demethylation agent, miR‑34b mimic or MET inhibitor and an anticancer drug.
- Published
- 2020
- Full Text
- View/download PDF
22. Erratum: Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors (Review).
- Author
-
Umene K, Banno K, Kisu I, Yanokura M, Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, and Aoki D
- Abstract
[This corrects the article DOI: 10.3892/br.2013.91.]., (Copyright: © Umene et al.)
- Published
- 2019
- Full Text
- View/download PDF
23. Mutations of RAS genes in endometrial polyps.
- Author
-
Takeda T, Banno K, Kobayashi Y, Adachi M, Yanokura M, Tominaga E, Kosaki K, and Aoki D
- Subjects
- Adult, Female, Humans, Polyps pathology, Uterine Diseases pathology, Exome genetics, GTP Phosphohydrolases genetics, Membrane Proteins genetics, Mutation, Polyps genetics, Proto-Oncogene Proteins p21(ras) genetics, Uterine Diseases genetics
- Abstract
Endometrial polyps are common, yet the molecular mechanisms underlying their formation and progression remain unclear. We examined gene mutations possibly related to the pathogenesis of endometrial polyps, as well as to their clinical features. Four premenopausal patients with endometrial polyps, who were not under drug treatment, were recruited. Whole exomes of endometrial polyps and peripheral blood lymphocytes were analyzed by next‑generation sequencing, and somatic mutations were derived by subtraction. Then, 35 samples of endometrial polyps and 12 samples of atypical polypoid adenomyoma were newly recruited to validate the identified mutations by polymerase chain reaction‑reverse sequence specific oligonucleotide method. The mutations were also analyzed in separate stromal and glandular components of the polyps after laser‑capture microdissection. Whole exome sequencing revealed that KRAS mutations were the only type of mutation detectable in multiple cases (2/4). Targeted mutation analysis revealed that 16 of 35 samples (45.7%) of endometrial polyps harbored RAS mutations. Mutation‑positive cases exhibited a significantly higher number of endometrial polyps (3.25±2.70 vs. 1.74±0.87, P=0.045). Laser‑capture microdissection in NRAS‑mutated endometrial polyps revealed that both stromal and glandular components harbored RAS mutations. There was no RAS mutation in 12 samples of atypical polypoid adenomyoma. This is the first report demonstrating that pathogenic RAS mutations are frequent in non‑treated endometrial polyps. RAS mutations may have an important role in tumorigenesis and in the formation of multiple endometrial polyps.
- Published
- 2019
- Full Text
- View/download PDF
24. Current status of uterine regenerative medicine for absolute uterine factor infertility.
- Author
-
Matoba Y, Kisu I, Sera A, Yanokura M, Banno K, and Aoki D
- Abstract
Though assisted reproduction technology has been developed, a treatment for absolute uterine factor infertility (AUFI), such as defects in the uterus, has not yet been established. Regenerative medicine has been developed and applied clinically over recent years; however, whole solid organs still cannot be produced. Though uterine regeneration has the potential to be a treatment for AUFI, there have been only a few studies on uterine regeneration involving the myometrium in vivo . In the present report, those relevant articles are reviewed. A literature search was conducted in PubMed with a combination of key words, and 10 articles were found, including nine in rat models and one in a mouse model. Of these studies, eight used scaffolds and two were performed without scaffolds. In four of these studies, scaffolds were re-cellularized with various cells. In the remaining four studies, scaffolds were transplanted alone, or other structures were used. Though the methods differed, the injured uterus recovered well, morphologically and functionally, in every study. Only 10 articles were relevant to our investigation, but the results were favorable, if limited to partial regeneration. Recently, uterus transplantation (UTx) has been investigated as a treatment for AUFI. However, UTx has many problems in the medical, ethical and social fields. Though the artificial uterus was also researched and some improvements in this technology were reported, it will take long time for this to reach a clinically applicable stage. Though the results of uterine regeneration studies were promising, these studies were conducted using animal models, so further human studies and trials are needed.
- Published
- 2019
- Full Text
- View/download PDF
25. Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: A case report.
- Author
-
Takeda T, Banno K, Yanokura M, Anko M, Kobayashi A, Sera A, Takahashi T, Adachi M, Kobayashi Y, Hayashi S, Nomura H, Hirasawa A, Tominaga E, and Aoki D
- Abstract
Synchronous endometrial and ovarian cancer (SEOC) is a rare entity among gynecological cancers, which exhibits endometrioid histology in its early stages and generally has a good prognosis. However, diagnosis is difficult and recent reports have demonstrated that most clinically diagnosed cases of SEOC have clonally related cancers, indicating metastatic cancer. The association of SEOC with Lynch syndrome is also not clearly understood. We herein present the case of a 41-year-old SEOC patient with MSH2 mutation. The endometrial cancer was an endometrioid adenocarcinoma and the ovarian cancer was mainly endometrioid, but also included a clear cell carcinoma with a borderline clear cell adenofibromatous component, indicating primary ovarian cancer. Both tumors exhibited microsatellite instability (MSI) and loss of expression of MSH2 and MSH6. The patient had a family history of colorectal and gastric cancers. Genetic analysis revealed a germline mutation in exon 6 of MSH2 (c.1042C>T, p.Gln348*) and the patient was diagnosed with Lynch syndrome. This MSH2 mutation has only been registered in one case in the InSiGHT variant databases and has not been reported in a gynecological tumor or SEOC to date. This case is a rare example of a patient with genetically diagnosed Lynch syndrome who also developed SEOC. This synchronous cancer is not common, but it may be caused by Lynch syndrome. Testing for MSI and immunohistochemistry for mismatch repair deficiency is necessary in cases with suspected SEOC.
- Published
- 2018
- Full Text
- View/download PDF
26. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer.
- Author
-
Takeda T, Tsuji K, Banno K, Yanokura M, Kobayashi Y, Tominaga E, and Aoki D
- Subjects
- Adult, Aged, Colorectal Neoplasms, Hereditary Nonpolyposis etiology, Colorectal Neoplasms, Hereditary Nonpolyposis genetics, DNA Mismatch Repair, Female, Humans, Microsatellite Instability, Middle Aged, MutL Protein Homolog 1 genetics, MutS Homolog 2 Protein genetics, Colorectal Neoplasms, Hereditary Nonpolyposis diagnosis, Early Detection of Cancer, Ovarian Neoplasms genetics, Risk Assessment
- Abstract
Objective: Lynch syndrome is a cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes. Lynch syndrome only causes about 0.4% of cases of ovarian cancer, which suggests that universal screening may not be cost-efficient. However, the frequency of Lynch syndrome in ovarian cancer is unclear in the Asian population. The goal of the study was to investigate a screening strategy using family history., Methods: The subjects were 129 patients with ovarian cancer. Clinical and family history were collected using a self-administered questionnaire, and Society of Gynecologic Oncology (SGO) criteria 2007 and PREMM₅ were used for risk assessment. Microsatellite instability, immunohistochemistry, and methylation of MMR genes were analyzed., Results: Of the 129 cases, 25 (19.4%) met the SGO criteria, and 4 of these 25 had MSI-high and MMR deficiency. Two cases had loss of MSH2 and MSH6, indicating MSH2 mutation, and the other two had loss of MLH1 and PMS2, including one without MLH1 methylation indicating MLH1 mutation. These results show that screening using family history can detect Lynch syndrome in 12.0% (3/25) of ovarian cancer cases. The 3 cases were positive for PREMM₅, but negative for Amsterdam II criteria and revised Bethesda guidelines. Genetic testing in one case with MSH2 and MSH6 deficiency confirmed the diagnosis of Lynch syndrome with MSH2 mutation., Conclusion: This is the first study of screening for Lynch syndrome in ovarian cancer using clinical and family history in an Asian population. This approach may be effective for diagnosis in these patients., Competing Interests: No potential conflict of interest relevant to this article was reported., (Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.)
- Published
- 2018
- Full Text
- View/download PDF
27. Aberrant chromatin remodeling in gynecological cancer.
- Author
-
Okawa R, Banno K, Iida M, Yanokura M, Takeda T, Iijima M, Kunitomi-Irie H, Nakamura K, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, and Aoki D
- Abstract
Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich interactive domain-containing protein 1A (ARID1A) and SWItch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 are remodeling factors that are mutated in numerous types of cancer. In gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma. Mutations of chromodomain helicase, DNA-binding protein 4 have been detected in 17-21% of endometrial serous cancer, and mutations of ARID1A and mixed-lineage leukemia 3 occur in 36 and 27% of uterine carcinosarcoma, respectively. These data suggest that aberrant chromatin remodeling is a potential cause of cancer, and have led to the development of novel proteins targeting these processes. Additional accumulation of information on the mechanisms of chromatin remodeling and markers for these events may promote personalized anticancer therapies.
- Published
- 2017
- Full Text
- View/download PDF
28. Recent findings on epigenetic gene abnormalities involved in uterine cancer.
- Author
-
Yanokura M, Banno K, Kobayashi Y, Nomura H, Hayashi S, Tominaga E, and Aoki D
- Abstract
Selective aberrant genetic effects that do not depend on abnormal DNA sequences are referred to as epigenetic abnormalities and are involved in carcinogenesis. In uterine cancer, various genes involved in apoptosis, cell cycle, DNA repair, cell proliferation and cell adhesion are abnormally methylated, resulting in gene silencing. Reversal of such epigenetic abnormalities in cancer cells is a potential strategy for cancer therapy, and studies on epigenetic abnormalities and treatment methods in uterine cancer are in progress. These include the evaluation of 5-hydroxymethylcytosine, which is present in cancer tissues at lower levels compared with those in normal tissues, as a prognostic marker in cervical cancer; combination therapy with 5-azacytidine and cisplatin; combination treatment focusing on tumor necrosis factor-related apoptosis-inducing ligand in cervical cancer; studies focusing on DNA mismatch repair in endometrial cancer; and use of a demethylating agent to reactivate tumor suppressor genes and inhibit tumor proliferation. Detection of epigenetic changes using biomarkers may be used for histological classification, evaluation of disease progression and identification of compounds that are able to modulate epigenetic changes and may be useful for uterine cancer treatment.
- Published
- 2017
- Full Text
- View/download PDF
29. New use of microsatellite instability analysis in endometrial cancer.
- Author
-
Kunitomi H, Banno K, Yanokura M, Takeda T, Iijima M, Nakamura K, Iida M, Adachi M, Watanabe K, Matoba Y, Kobayashi Y, Tominaga E, and Aoki D
- Abstract
The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche, delayed menopause, late marriage, and declining birth rate have resulted in an increase in the number of endometrial cancer cases over the last few decades. Although surgical therapy is sufficient for early endometrial cancer, there is no effective therapy for patients with advanced and recurrent endometrial cancer. The oncogenic mechanism of endometrial cancer involves microsatellite instability (MSI) caused by dysfunction of DNA mismatch repair genes in 30% of patients. Immune checkpoint inhibitors, including anti-programmed death (PD)-1 and anti-PD-ligand 1 antibodies, are of interest as novel anticancer drugs; however, these drugs are currently expensive, and there is a need to select patients who will benefit from their use. The use of MSI analysis as a predictive biomarker for the therapeutic efficacy of these drugs may be useful for reducing the costs of drug therapy.
- Published
- 2017
- Full Text
- View/download PDF
30. Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer.
- Author
-
Yanokura M, Banno K, Adachi M, Aoki D, and Abe K
- Subjects
- Adenomatous Polyposis Coli Protein genetics, Adult, Aged, Antigens, CD, Cadherins genetics, CpG Islands genetics, Endometrial Neoplasms pathology, Epigenesis, Genetic genetics, Female, Gene Expression Regulation, Neoplastic, Genome, Human genetics, Humans, Middle Aged, MutL Protein Homolog 1 genetics, Mutation, Promoter Regions, Genetic, Biomarkers, Tumor genetics, DNA Methylation genetics, Endometrial Neoplasms genetics, MicroRNAs genetics
- Abstract
Aberrant DNA methylation is widely observed in many cancers. Concurrent DNA methylation of multiple genes occurs in endometrial cancer and is referred to as the CpG island methylator phenotype (CIMP). However, the features and causes of CIMP-positive endometrial cancer are not well understood. To investigate DNA methylation features characteristic to CIMP-positive endometrial cancer, we first classified samples from 25 patients with endometrial cancer based on the methylation status of three genes, i.e. MLH1, CDH1 (E-cadherin) and APC: CIMP-high (CIMP-H, 2/25, 8.0%), CIMP-low (CIMP-L, 7/25, 28.0%) and CIMP-negative (CIMP(-), 16/25, 64.0%). We then selected two samples each from CIMP-H and CIMP(-) classes, and analyzed DNA methylation status of both normal (peripheral blood cells: PBCs) and cancer tissues by genome-wide, targeted bisulfite sequencing. Genomes of the CIMP-H cancer tissues were significantly hypermethylated compared to those of the CIMP(-). Surprisingly, in normal tissues of the CIMP-H patients, promoter region of the miR-663a locus is hypermethylated relative to CIMP(-) samples. Consistent with this finding, miR-663a expression was lower in the CIMP-H PBCs than in the CIMP(-) PBCs. The same region of the miR663a locus is found to be highly methylated in cancer tissues of both CIMP-H and CIMP(-) cases. This is the first report showing that aberrant DNA methylation of the miR-663a promoter can occur in normal tissue of the cancer patients, suggesting a possible link between this epigenetic abnormality and endometrial cancer. This raises the possibility that the hypermethylation of the miR-663a promoter represents an epimutation associated with the CIMP-H endometrial cancers. Based on these findings, relationship of the aberrant DNA methylation and CIMP-H phenotype is discussed.
- Published
- 2017
- Full Text
- View/download PDF
31. Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
- Author
-
Iijima M, Banno K, Okawa R, Yanokura M, Iida M, Takeda T, Kunitomi-Irie H, Adachi M, Nakamura K, Umene K, Nogami Y, Masuda K, Tominaga E, and Aoki D
- Abstract
Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 ( TP53 ) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma. Genome-wide analysis of endometrial cancers has led to the establishment of four subgroups: Polymerase ultramutated, microsatellite instability hypermutated, genome copy-number low and genome copy-number high. These results may facilitate the improvement of the prediction of patient prognosis and therapeutic sensitivity in various types of gynecologic cancer. The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on TP53 mutations, the efficacy of poly (ADP-ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway. Important results have been revealed by genome-wide analyses; however, the pathogenic underlying mechanisms of gynecologic cancer will require further studies and multilateral evaluation using epigenetic, transcriptomic and proteomic analyses, in addition to genomic analysis.
- Published
- 2017
- Full Text
- View/download PDF
32. Carcinoma of the lower uterine segment diagnosed with Lynch syndrome based on MSH6 germline mutation: A case report.
- Author
-
Adachi M, Banno K, Masuda K, Yanokura M, Iijima M, Takeda T, Kunitomi H, Kobayashi Y, Yamagami W, Hirasawa A, Kameyama K, Sugano K, and Aoki D
- Subjects
- Female, Germ-Line Mutation, Humans, Middle Aged, Carcinoma, Endometrioid genetics, Colorectal Neoplasms, Hereditary Nonpolyposis genetics, DNA-Binding Proteins genetics, Uterine Neoplasms genetics
- Abstract
Endometrial cancer in the lower uterine segment (LUS) is associated with Lynch syndrome with MLH1 or MSH2 germline mutation. Here, we report a case of carcinoma of the LUS diagnosed with Lynch syndrome based on MSH6 germline mutation in a 46-year-old woman with abnormal vaginal bleeding. She had had rectal cancer at age 39 with a family history of colon cancer (father, 75 years), pancreatic cancer (paternal grandmother, 74 years), and colon cancer (maternal grandmother, 85 years). Magnetic resonance imaging showed a tumor in the LUS. Endometrial biopsy revealed endometrioid adenocarcinoma G1. As her cancer history met the revised Bethesda criteria, we examined microsatellite instability and the result was negative, but loss of the MSH6 expression was detected by immunohistochemistry. Genetic testing revealed deleterious germline mutation of MSH6, which was compatible with Lynch syndrome. To our knowledge, this is the first case of endometrial carcinoma of the LUS with MSH6 germline mutation., (© 2016 Japan Society of Obstetrics and Gynecology.)
- Published
- 2017
- Full Text
- View/download PDF
33. Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment.
- Author
-
Kiba A, Banno K, Yanokura M, Asada M, Nakayama Y, Aoki D, and Watanabe T
- Subjects
- Adult, Biomarkers, Tumor metabolism, Endometriosis genetics, Female, Humans, Middle Aged, Ovarian Neoplasms genetics, Signal Transduction, Antineoplastic Agents, Hormonal therapeutic use, Endometriosis drug therapy, Endometriosis metabolism, Leuprolide therapeutic use, MicroRNAs metabolism, Ovarian Neoplasms drug therapy, Ovarian Neoplasms metabolism
- Abstract
Aim: Micro ribonucleic acids (miRNAs) play an important pathological role in endometriosis. Leuprolide acetate, an analog of gonadotropin-releasing hormone, is widely used to treat endometriosis; however, the molecular mechanisms involved in endometriotic tissue regression remain unclear. We performed miRNA expression profiling of clinical ovarian endometrioma to obtain insight into the effects of leuprolide acetate treatment., Methods: We obtained clinical samples from nine normal eutopic endometrium, eight ovarian endometriotic, and 12 leuprolide acetate-treated endometriotic tissues. We compared the miRNA expression profiles of the three groups by performing TaqMan Array MicroRNA Card and bioinformatic analysis., Results: Two miRNAs, miR-939 and miR-154, were upregulated in endometriotic tissue and downregulated in leuprolide acetate-treated endometriotic tissue. Five miRNAs (miR-146a, miR-142-3p, miR-136*, miR-125b-1* and miR-15b*) were unchanged in endometriotic tissue but were upregulated under leuprolide acetate treatment. Ingenuity pathway analysis using predicted target genes for the seven identified miRNAs suggested the involvement of a range of pathways, including axonal guidance, bone morphogenetic protein, phosphatase and tensin homolog and nitric oxide signaling; molecular mechanisms of cancer; and the adipogenesis and signal transducer and activator of transcription 3 (STAT3) pathways., Conclusions: To our knowledge, this is the first report profiling the miRNAs of endometrioma under leuprolide acetate treatment. The expression of seven miRNAs was modulated, concomitant with the disease state. This result gives new insight into the effects of leuprolide acetate treatment. Further investigation using quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry will allow us to validate the results of this study and to explore new therapeutic targets and biomarkers of endometriosis., (© 2016 Japan Society of Obstetrics and Gynecology.)
- Published
- 2016
- Full Text
- View/download PDF
34. Methylation Analysis of DNA Mismatch Repair Genes Using DNA Derived from the Peripheral Blood of Patients with Endometrial Cancer: Epimutation in Endometrial Carcinogenesis.
- Author
-
Takeda T, Banno K, Yanokura M, Adachi M, Iijima M, Kunitomi H, Nakamura K, Iida M, Nogami Y, Umene K, Masuda K, Kobayashi Y, Yamagami W, Hirasawa A, Tominaga E, Susumu N, and Aoki D
- Abstract
Germline mutation of DNA mismatch repair (MMR) genes is a cause of Lynch syndrome. Methylation of MutL homolog 1 ( MLH1 ) and MutS homolog 2 ( MSH2 ) has been detected in peripheral blood cells of patients with colorectal cancer. This methylation is referred to as epimutation. Methylation of these genes has not been studied in an unselected series of endometrial cancer cases. Therefore, we examined methylation of MLH1 , MSH2 , and MSH6 promoter regions of peripheral blood cells in 206 patients with endometrial cancer using a methylation-specific polymerase chain reaction (MSP). Germline mutation of MMR genes, microsatellite instability (MSI), and immunohistochemistry (IHC) were also analyzed in each case with epimutation. MLH1 epimutation was detected in a single patient out of a total of 206 (0.49%)-1 out of 58 (1.72%) with an onset age of less than 50 years. The patient with MLH1 epimutation showed high level MSI (MSI-H), loss of MLH1 expression and had developed endometrial cancer at 46 years old, complicated with colorectal cancer. No case had epimutation of MSH2 or MSH6 . The MLH1 epimutation detected in a patient with endometrial cancer may be a cause of endometrial carcinogenesis. This result indicates that it is important to check epimutation in patients with endometrial cancer without a germline mutation of MMR genes., Competing Interests: The authors declare no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
35. Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.
- Author
-
Irie H, Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, and Aoki D
- Abstract
Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma and breast cancer. The anticancer action of metformin involves the enhancement of phosphorylation of liver kinase B1, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin, which reduces cell growth. Metformin is anticipated to exert antitumor effects in gynecological cancer, and its efficacy for the treatment of endometrial, breast and ovarian cancer has been suggested in preclinical studies and clinical trials. Although the effect of metformin on cervical cancer remains to be examined in clinical trials, its antitumor effects have been reported in preclinical studies. Thus, the use of metformin for the treatment of gynecological cancer may become a successful example of drug repositioning, following establishment of the drug's antitumor effects, risk evaluation, screening and validation of efficacy.
- Published
- 2016
- Full Text
- View/download PDF
36. ARID1A gene mutation in ovarian and endometrial cancers (Review).
- Author
-
Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, and Aoki D
- Subjects
- DNA-Binding Proteins, Female, Humans, Endometrial Neoplasms genetics, Mutation, Nuclear Proteins genetics, Ovarian Neoplasms genetics, Transcription Factors genetics
- Abstract
The AT-rich interacting domain‑containing protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome‑wide analyses with next‑generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis‑associated ovarian cancer, including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis‑associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis‑associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus, a small molecule inhibitor of the PI3K/AKT pathway, for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular‑targeted drug can inhibit proliferation of ARID1A‑mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis, to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development, survival and progression of cancer cells.
- Published
- 2016
- Full Text
- View/download PDF
37. Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment.
- Author
-
Kiba A, Banno K, Yanokura M, Asada M, Nakayama Y, Aoki D, and Watanabe T
- Subjects
- Adult, Antineoplastic Agents, Hormonal therapeutic use, Cluster Analysis, Endometriosis pathology, Female, Gene Expression Profiling, Humans, Leuprolide therapeutic use, Middle Aged, Ovary pathology, Antineoplastic Agents, Hormonal pharmacology, Endometriosis drug therapy, Leuprolide pharmacology, Ovary drug effects, Ovary metabolism
- Abstract
Aim: Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometriotic tissue, however, remain to be elucidated. In this study, we performed genome-wide gene expression profiling of clinical specimens of ovarian endometrioma to obtain insight into the effects of leuprolide acetate treatment., Methods: We obtained clinical samples from nine normal eutopic endometrium tissues, eight ovarian endometriotic tissues, and 12 leuprolide acetate-treated endometriotic tissues. We compared the gene expression profiles of the three groups using Affymetrix GeneChip Human genome arrays and bioinformatic analysis, including molecular concept analysis., Results: Leuprolide acetate-treated endometriotic tissue showed downregulated genes associated with the biological functions of steroid hormone regulation, cell proliferation, inflammation, and intracellular signaling. These genes included PTGDS, GRP, APLP2, PLTP, and FGFRL1. In contrast, genes upregulated by leuprolide acetate treatment were associated with cell growth inhibition and apoptosis. These genes included CARD11 and USP18., Conclusions: These preliminary results based on GeneChip analysis suggest that leuprolide acetate treatment induces a modulation of gene expression that allows for cooperative alterations in disease state. This study gives new insight into the effects of leuprolide acetate treatment. Further investigations with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry are needed to validate this study and to explore new therapeutic targets and biomarkers of endometriosis., (© 2015 Japan Society of Obstetrics and Gynecology.)
- Published
- 2015
- Full Text
- View/download PDF
38. Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.
- Author
-
Umene K, Yanokura M, Banno K, Irie H, Adachi M, Iida M, Nakamura K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, and Aoki D
- Subjects
- Animals, Antineoplastic Agents, Phytogenic therapeutic use, Aurora Kinase A antagonists & inhibitors, Cell Line, Tumor, Disease-Free Survival, Endometrial Neoplasms enzymology, Female, Gene Knockdown Techniques, Humans, Mice, Paclitaxel therapeutic use, RNA, Small Interfering pharmacology, Up-Regulation drug effects, Xenograft Model Antitumor Assays, Antineoplastic Agents, Phytogenic administration & dosage, Aurora Kinase A metabolism, Endometrial Neoplasms drug therapy, Endometrial Neoplasms pathology, Paclitaxel administration & dosage, RNA, Small Interfering administration & dosage
- Abstract
Aurora kinase A (AURKA) regulates the cell cycle checkpoint and maintains genomic integrity. AURKA is overexpressed in various malignant tumors and its upregulation induces chromosomal instability, which leads to aneuploidy and cell transformation. To investigate the role of AURKA in endometrial cancer, we evaluated the association of immunohistochemical expression of AURKA with clinicopathological factors. Furthermore, we examined the effects of AURKA inhibition by transfected siRNA in HEC-1B cells on colony-forming ability, invasion and migration capacity, and chemosensitivity. Immunohistochemical staining showed that overexpression of AURKA was significantly associated with tumor grade (P<0.05) and poor histologic differentiation (P<0.05). The recurrence rate also tended to be high in cases with overexpression of AURKA (P<0.1) and these cases also had a tendency for shorter disease-free survival (DFS) (P<0.1). AURKA inhibition in endometrial cancer cell lines significantly decreased cell growth, invasion and migration (P<0.05), and increased chemosensitivity to paclitaxel. We also evaluated the efficacy of a combination of AURKA siRNA and paclitaxel against subcutaneous tumors formed in a nude mouse. After treatment, the tumor volume shrank significantly compared to treatment with paclitaxel only (P<0.05). To our knowledge, this is the first study in endometrial carcinoma to show a correlation between overexpression of AURKA and tumor grade, histological type and sensitivity to paclitaxel. AURKA is a promising therapeutic target in endometrial cancer and the combination therapy with AURKA inhibitors and paclitaxel could be effective for endometrial cancer that is resistant to conventional treatment and has a poor prognosis.
- Published
- 2015
- Full Text
- View/download PDF
39. Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.
- Author
-
Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, and Aoki D
- Abstract
Risk-reducing surgery (RRS) is defined as a prophylactic approach with removal of organs at high risk of developing cancer, which is performed in cases without lesions or absence of clinically significant lesions. Hereditary gynecological cancers for which RRS is performed include hereditary breast and ovarian cancer (HBOC) and Lynch syndrome. For HBOC, RRS in the United States (US) is recommended for women with mutations in the breast cancer susceptibility ( BRCA ) 1 and BRCA2 genes and bilateral salpingo-oophorectomy (BSO) is generally performed. This procedure may reduce the risk of breast, ovarian, Fallopian tube and primary peritoneal cancer, although ovarian deficiency symptoms occur postoperatively. For Lynch syndrome, RRS in the US is considered for postmenopausal women or for women who do not desire to bear children and BSO and hysterectomy are usually performed. This approach may reduce the risk of endometrial and ovarian cancer, although ovarian deficiency symptoms also occur. For RRS, there are several issues that must be addressed to reduce the risk of cancer development in patients with HBOC or Lynch syndrome. To the best of our knowledge, this is the first review to discuss RRS with a focus on hereditary gynecological cancer.
- Published
- 2015
- Full Text
- View/download PDF
40. MicroRNAS in endometrial cancer: recent advances and potential clinical applications.
- Author
-
Yanokura M, Banno K, Iida M, Irie H, Umene K, Masuda K, Kobayashi Y, Tominaga E, and Aoki D
- Abstract
Endometrial cancer is a common malignant gynecological tumor, but there are few biomarkers that are useful for early and accurate diagnosis and few treatments other than surgery. However, use of microRNAs (miRNAs) that induces gene downregulation in cells may permit effective and minimally invasive diagnosis and treatment. In endometrial cancer cells, expression levels of miRNAs including miR-185, miR-210 and miR-423 are upregulated and those of miR-let7e, miR-30c and miR-221 are downregulated compared to normal tissues, and these miRNAs are involved in carcinogenesis, invasion and metastasis. miRNAs with expression changes such as miR-181b, miR-324-3p and miR-518b may be used as prognostic biomarkers and transfection of miR-152 may inhibit cancer growth. However, most current studies of miRNAs are at a basic level and further work is needed to establish clinical applications targeting miRNAs.
- Published
- 2015
- Full Text
- View/download PDF
41. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer.
- Author
-
Banno K, Iida M, Yanokura M, Irie H, Masuda K, Kobayashi Y, Tominaga E, and Aoki D
- Subjects
- AMP-Activated Protein Kinases metabolism, Cyclooxygenase 2 Inhibitors pharmacology, Drug Therapy, Combination methods, Female, Humans, Metformin pharmacology, Peroxisome Proliferator-Activated Receptors metabolism, Ritonavir pharmacology, Drug Repositioning methods, Drug Repositioning trends, Genital Neoplasms, Female drug therapy
- Abstract
The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX-2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K-Akt-mTOR pathway by activating LKB1-AMPK and reduction of insulin and insulin-like growth factor-1 due to AMPK activation. COX-2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX-2. PGE2 maintains high expression of COX-2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX-2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug reactions. Thus, drug repositioning may become a key approach for gynecologic cancer in drug discovery.
- Published
- 2015
- Full Text
- View/download PDF
42. Features of ovarian cancer in Lynch syndrome (Review).
- Author
-
Nakamura K, Banno K, Yanokura M, Iida M, Adachi M, Masuda K, Ueki A, Kobayashi Y, Nomura H, Hirasawa A, Tominaga E, and Aoki D
- Abstract
Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9-2.7%. Lynch syndrome accounts for 10-15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65-75% of these cancers. The lifetime risk for ovarian cancer in families with Lynch syndrome is ~8%, which is lower than colorectal and endometrial cancers, and ovarian cancer is not listed in the Amsterdam Criteria II. More than half of sporadic ovarian cancers are diagnosed in stage III or IV, but ≥80% of ovarian cancers in Lynch syndrome are diagnosed in stage I or II. Ovarian cancers in Lynch syndrome mostly have non-serous histology and different properties from those of sporadic ovarian cancers. A screening method for ovarian cancers in Lynch syndrome has yet to be established and clinical studies of prophylactic administration of oral contraceptives are not available. However, molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer. Inhibitors of the phosphatidylinositol 3-kinase/mammalian target of the rapamycin pathway and anti-epidermal growth factor antibodies may have efficacy for the disease. To the best of our knowledge, this is the first review focusing on ovarian cancer in Lynch syndrome.
- Published
- 2014
- Full Text
- View/download PDF
43. Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).
- Author
-
Iida M, Banno K, Yanokura M, Nakamura K, Adachi M, Nogami Y, Umene K, Masuda K, Kisu I, Iwata T, Tanaka K, and Aoki D
- Abstract
Cervical cancer ranks high among the causes of female cancer mortalities and is an important disease in developing and developed countries. Current diagnosis of cervical cancer depends on colposcopy, pathological diagnosis and preoperative diagnosis using methods, including magnetic resonance imaging and computed tomography. Advanced cervical cancer has a poor prognosis. The tumor marker squamous cell carcinoma is conventionally used for screening, but recent studies have revealed the mechanisms of carcinogenesis and the factors associated with a poor prognosis in cervical cancer. These include epigenetic biomarkers, with the methylation level of the checkpoint with forkhead and ring finger gene being potentially useful for predicting the malignancy of cervical cancer and sensitivity to treatment with paclitaxel. The extent of methylation of the Werner DNA helicase gene is also useful for determining sensitivity to an anticancer agent, CPT-11. In addition to epigenetic changes, the expression levels of hypoxia-inducible factor 1α subunit, epidermal growth factor receptor and cyclooxygenase-2 have been reported as possible biomarkers in cervical cancer. Novel prognostic factors, including angiogenic factors, fragile histidine triad, thymidylate synthase, glucose-related protein 58 and mucin antigens, have also been described, and hemoglobin and platelets may also be significant prognostic biomarkers. Utilization of these biomarkers may facilitate personalized treatment and improved outcomes in cervical cancer.
- Published
- 2014
- Full Text
- View/download PDF
44. Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics.
- Author
-
Banno K, Yanokura M, Iida M, Masuda K, and Aoki D
- Subjects
- Cell Proliferation, Cell Transformation, Neoplastic, DNA Methylation, DNA Mismatch Repair, Endometrial Neoplasms metabolism, Endometrial Neoplasms pathology, Endometrium pathology, Female, Gene Expression Regulation, Neoplastic, Gene Silencing, Humans, MicroRNAs metabolism, Microsatellite Instability, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins metabolism, Carcinogenesis, Endometrial Neoplasms genetics, Endometrium metabolism, Epigenesis, Genetic, Models, Biological, Mutation, Neoplasm Proteins genetics
- Abstract
Endometrial cancer is increasing worldwide and the number of patients with this disease is likely to continue to grow, including younger patients. Many endometrial cancers show estrogen-dependent proliferation, but the carcinogenic mechanisms are unknown or not completely explained beyond mutations of single oncogenes and tumor suppressor genes. Possible carcinogenic mechanisms include imbalance between endometrial proliferation by unopposed estrogen and the mismatch repair (MMR) system; hypermethylation of the MMR gene hMLH1; mutation of PTEN, β-catenin and K-ras genes in type I endometrial cancer and of HER-2/neu and p53 genes in type II endometrial cancer; hypermethylation of SPRY2, RASSF1A, RSK4, CHFR and CDH1; and methylation of tumor suppressor microRNAs, including miR-124, miR-126, miR-137, miR-491, miR-129-2 and miR-152. Thus, it is likely that the carcinogenic mechanisms of endometrial cancer involve both genetic and epigenetic changes. Mutations and methylation of MMR genes induce various oncogenic changes that cause carcinogenesis, and both MMR mutation in germ cells and methylation patterns may be inherited over generations and cause familial tumorigenesis. Determination of the detailed carcinogenic mechanisms will be useful for prevention and diagnosis of endometrial cancer, risk assessment, and development of new treatment strategies targeting MMR genes., (© 2014 The Authors. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.)
- Published
- 2014
- Full Text
- View/download PDF
45. MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment.
- Author
-
Banno K, Iida M, Yanokura M, Kisu I, Iwata T, Tominaga E, Tanaka K, and Aoki D
- Subjects
- Animals, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Cell Transformation, Viral, DNA Methylation, Female, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Humans, Lymphatic Metastasis, MicroRNAs therapeutic use, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms therapy, MicroRNAs genetics, Uterine Cervical Neoplasms genetics
- Abstract
Cervical cancer is a female-specific disease with a high incidence and mortality. MicroRNAs (miRNAs) are implicated in posttranscriptional regulation of gene expression and in the pathogenic mechanisms of cancer, suggesting their importance in diagnosis and treatment. miRNAs may have roles in the pathogenesis of cervical cancer based on the increases or decreases in several specific miRNAs found in patients with this disease. The miRNAs implicated in cervical cancer are miR-21, miR-126, and miR-143, and clinical application of these miRNAs for diagnosis and treatment is under investigation. Methods for diagnosis of cervical cancer include analysis of changes in the levels of specific miRNAs in serum and determination of aberrant hypermethylation of miRNAs. Supplementation of miR-143 or inhibition of miR-21 activity in vivo may be therapeutic strategy for cervical cancer. Previous approaches to development of siRNA as a drug have provided information for establishment of therapy based on these approaches, and an anti-miR-21 inhibitor has been developed. miRNAs also have effects on drug resistance and may be useful in combination therapy with other drugs.
- Published
- 2014
- Full Text
- View/download PDF
46. Application of microRNA in diagnosis and treatment of ovarian cancer.
- Author
-
Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Nomura H, Kataoka F, Tominaga E, and Aoki D
- Subjects
- Female, Gene Expression Regulation, Neoplastic, Humans, Biomarkers, Tumor, MicroRNAs, Ovarian Neoplasms diagnosis, Ovarian Neoplasms genetics, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology
- Abstract
Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.
- Published
- 2014
- Full Text
- View/download PDF
47. Indocyanine green fluorescence imaging in the pregnant cynomolgus macaque: childbearing is supported by a unilateral uterine artery and vein alone?
- Author
-
Kisu I, Banno K, Yanokura M, Nogami Y, Umene K, Tsuji K, Masuda K, Ueki A, Kobayashi Y, and Aoki D
- Subjects
- Animals, Cesarean Section, Female, Hemodynamics, Humans, Macaca fascicularis, Pregnancy, Pregnancy Trimester, Third, Coloring Agents pharmacology, Indocyanine Green chemistry, Optical Imaging methods, Uterine Artery, Uterus blood supply
- Abstract
Purpose: Uterine blood flow is required for the maintenance of uterine viability in pregnancy and delivery, but it is unknown how many vessels are necessary for maintenance of uterine viability. The objective of this study was to examine whether unilateral uterine vessels provide sufficient nutrition in pregnancy in a cynomolgus macaque and to evaluate hemodynamics of pregnant uterus by indocyanine green (ICG) fluorescence imaging., Methods: A cynomolgus macaque with uterine blood flow maintained by the right uterine artery and vein alone was made pregnant. Hemodynamics of the uterus in the third trimester was evaluated by ICG fluorescence imaging., Results: Pregnancy was maintained with the right uterine artery and vein. An appropriate-for-date infant was delivered by Cesarean section. ICG fluorescence imaging showed that the uterine body was imaged from the right side to the center; furthermore, collateral circulation was present from the right uterine artery toward the left uterine artery, with expanded blood flow to the left uterine body., Conclusion: Pregnancy and delivery were achieved in a cynomolgus macaque with a unilateral right uterine artery and vein. Blood flow to the side without the artery was complemented by vascularization of collateral circulation to the uterine artery.
- Published
- 2013
- Full Text
- View/download PDF
48. Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review).
- Author
-
Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Hirasawa A, and Aoki D
- Abstract
Peutz-Jeghers syndrome (PJS) is an autosomal dominant disease that is characterized by gastrointestinal hamartomatous polyposis and mucocutaneous melanin spots. The tumor suppressor gene, STK11/LKB1 , which is located on chromosome 19p13.3, has been reported to be responsible for this condition. PJS is complicated by benign and malignant tumors of various organs and complications from rare diseases, including sex cord tumor with annular tubules (SCTAT) and minimal deviation adenocarcinoma (MDA), which have also recently attracted attention in the field of gynecology. Among the total MDA cases, 10% are complications of PJS, and mutations in the STK11 gene are closely associated with the development and prognosis of MDA. Furthermore, a new type of uterine cervical tumor, lobular endocervical glandular hyperplasia (LEGH), has been identified and has been predicted to be a precancerous lesion of MDA. The first case of LEGH induced by a germline STK11 mutation has also been described. A high risk of endometrial cancer in PJS has also been reported. These developments suggest that PJS is an important syndrome of hereditary gynecological tumors that requires further study.
- Published
- 2013
- Full Text
- View/download PDF
49. Current status of molecular-targeted drugs for endometrial cancer (Review).
- Author
-
Nogami Y, Banno K, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, and Aoki D
- Abstract
Endometrial cancer is a common gynecological malignant tumor in Western countries and its incidence has also been on the increase in Asia. Genetic abnormalities related to onset and progression of malignancy in the endometrial membrane and signaling system have been identified and the developmental mechanism of endometrial cancer is becoming elucidated. The identification of the molecules related to these abnormalities has led to new potential treatment regimens for endometrial cancer, using molecular-targeted drugs. The current chemotherapy for endometrial cancer often causes systemic side effects that require discontinuation of the treatment. Furthermore, a treatment regimen for cancers of rare histological types has not been established. Recent studies on endometrial cancer revealed patterns of genetic disorders that differ among the histological types. Genetic and molecular information that underlie pathological changes and is associated with DNA mismatch repair genes and epigenetic regulation was also identified. Targeting of these mechanisms with molecular-targeted drugs has been performed with the aim of linking treatment to the carcinogenic mechanism at the molecular and genetic levels. However, the response rates with single-agent therapy are generally low and several problems remain unresolved. Trials of combinations of molecular-targeted drugs with currently available treatments and identification of factors determining sensitivity are required to overcome these difficulties.
- Published
- 2013
- Full Text
- View/download PDF
50. Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer.
- Author
-
Banno K, Nogami Y, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Susumu N, and Aoki D
- Subjects
- DNA Methylation genetics, Endometrial Neoplasms pathology, Epigenesis, Genetic, Female, Gene Expression Regulation, Neoplastic, Humans, MicroRNAs genetics, MicroRNAs metabolism, Biomarkers, Tumor genetics, Endometrial Neoplasms diagnosis, Endometrial Neoplasms genetics
- Abstract
The recent increase in the frequency of endometrial cancer has emphasized the need for accurate diagnosis and improved treatment. The current diagnosis is still based on conventional pathological indicators, such as clinical stage, tumor differentiation, invasion depth and vascular invasion. However, the genetic mechanisms underlying endometrial cancer have gradually been determined, due to developments in molecular biology, leading to the possibility of new methods of diagnosis and treatment planning. New candidate biomarkers for endometrial cancer include those for molecular epigenetic mutations, such as microRNAs. These biomarkers may permit earlier detection of endometrial cancer and prediction of outcomes and are likely to contribute to future personalized therapy for endometrial cancer.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.